HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous benztropine and propranolol challenges in tardive akathisia.

Abstract
We challenged five patients suffering from tardive akathisia (TA) with intravenous benztropine (2 mg), propranolol (1 mg) and placebo (saline) using a random, double-blind cross-over design to examine the effects of the drugs on the subjective, objective and global manifestations of neuroleptic-induced akathisia. Benztropine produced a marginally significant, and propranolol a significant improvement in the overall manifestations of the disorder. The patients demonstrated a considerable placebo effect and marked variation in their responses to the drugs. The implications of these findings for the pathophysiology of TA in relation to acute akathisia and tardive dyskinesia are discussed.
AuthorsP Sachdev, C Loneragan
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 113 Issue 1 Pg. 119-22 ( 1993) ISSN: 0033-3158 [Print] Germany
PMID7862817 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Benztropine
  • Propranolol
Topics
  • Adult
  • Akathisia, Drug-Induced (drug therapy, physiopathology)
  • Anxiety (psychology)
  • Benztropine (administration & dosage, pharmacology)
  • Cross-Over Studies
  • Double-Blind Method
  • Dyskinesia, Drug-Induced (physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Propranolol (administration & dosage, pharmacology)
  • Schizophrenia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: